Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
INDP 
Indaptus Therapeutics Inc (INDP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: INDP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $25
1 Year Target Price $25
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.79% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.34M USD | Price to earnings Ratio - | 1Y Target Price 25 |
Price to earnings Ratio - | 1Y Target Price 25 | ||
Volume (30-day avg) 1 | Beta 1 | 52 Weeks Range 2.22 - 58.24 | Updated Date 10/13/2025 |
52 Weeks Range 2.22 - 58.24 | Updated Date 10/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -37.38 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -136.55% | Return on Equity (TTM) -755.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4351614 | Price to Sales(TTM) - |
Enterprise Value 4351614 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.03 | Shares Outstanding 1106529 | Shares Floating 889328 |
Shares Outstanding 1106529 | Shares Floating 889328 | ||
Percent Insiders 19.63 | Percent Institutions 4.72 |
Upturn AI SWOT
Indaptus Therapeutics Inc
Company Overview
History and Background
Indaptus Therapeutics Inc. is a biotechnology company focused on developing innovative cancer therapies. Founded in 2017, it leverages its proprietary technology platform to create novel immunotherapeutic approaches.
Core Business Areas
- Alpha-Lytic Peptide (ALP) Platform: Indaptus' primary focus is the development of therapies based on its ALP technology. This platform is designed to target and disrupt the tumor microenvironment, enhancing the efficacy of other cancer treatments.
- Immuno-Oncology: The company is engaged in the research and development of immuno-oncology products aimed at stimulating the immune system to fight cancer.
Leadership and Structure
The company has a leadership team comprised of experienced biotechnology executives and scientists. Details on specific individuals and the precise organizational structure are readily available in their SEC filings and on the company website.
Top Products and Market Share
Key Offerings
- ITX-1105: ITX-1105, the company's lead product candidate, is an ALP-based therapeutic targeting the tumor microenvironment. Currently in pre-clinical and early clinical development, market share data isn't available at this stage. Competitors include companies developing similar immunotherapies and tumor microenvironment-targeting agents. Exact competitors are dependent on the specific mechanisms of action and stage of development of other therapies.
Market Dynamics
Industry Overview
The biotechnology industry, particularly the immuno-oncology sector, is characterized by intense competition, rapid innovation, and high regulatory hurdles. There's a significant need for novel therapies that overcome treatment resistance and improve patient outcomes.
Positioning
Indaptus is positioned as an innovative player in the immuno-oncology field, focusing on its unique ALP technology to target the tumor microenvironment. Its competitive advantage lies in the potential of its platform to enhance the efficacy of existing and emerging cancer treatments.
Total Addressable Market (TAM)
The global oncology market is estimated to reach hundreds of billions of dollars. Indaptus is aiming to capture a portion of this market by developing innovative therapies. The specific portion they might capture depends on the clinical success of their product and the market penetration.
Upturn SWOT Analysis
Strengths
- Proprietary ALP technology platform
- Focus on a validated therapeutic target (tumor microenvironment)
- Experienced management team
- Potential for combination therapies with existing treatments
Weaknesses
- Early stage of development (high risk)
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on the success of a single technology platform
- High competition in the immuno-oncology space
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of the ALP platform to other disease areas
- Positive clinical trial results demonstrating efficacy
- Breakthrough Therapy designation from regulatory agencies
Threats
- Failure of clinical trials
- Regulatory hurdles and delays
- Competition from other immuno-oncology therapies
- Patent challenges
- Economic downturn affecting funding for biotechnology companies
Competitors and Market Share
Key Competitors
- MRTX
- NK
- AGEN
Competitive Landscape
Indaptus has a novel technology and focuses on a different target, however it has much less funding and is not as advanced as its competitors.
Growth Trajectory and Initiatives
Historical Growth: As a relatively new company, historical growth data is limited. Growth will be primarily driven by the advancement of its product pipeline.
Future Projections: Future growth is contingent on successful clinical trials and regulatory approvals. Analyst estimates are needed to provide specific projections.
Recent Initiatives: Focus on clinical trials for ITX-1105 and explore further applications of the ALP platform. Specific initiatives would be found in their press releases.
Summary
Indaptus Therapeutics is an early-stage biotech company with a promising technology platform targeting the tumor microenvironment. Its success hinges on positive clinical trial results and securing partnerships. The company faces significant challenges, including competition from larger players and the inherent risks associated with drug development. However, its innovative approach and experienced team offer potential for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Company website
- Yahoo Finance
- MarketWatch
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Indaptus Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2015-08-04 | CEO & Director Mr. Jeffrey A. Meckler J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://indaptusrx.com |
Full time employees 7 | Website https://indaptusrx.com | ||
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.